Bond’s Commercial Director Phil Groom attended Medica, the leading international trade fair for the medical sector, earlier this month. Here he gives his perspective on the first in-person conference at which Bond has exhibited in almost two years.
Medica is the world’s largest medtech trade fair, attracting tens of thousands of visitors and exhibitors from around the globe to Dusseldorf, Germany, every year.
As this was the first time it had been held since 2019, I was interested to see how the market, and people’s attitudes, might have changed as a result of the Covid-19 pandemic.
My main takeaway was that digital is becoming mainstream in a way it hasn’t up until now. Of course, a lot of businesses, including Bond, have been developing cutting edge digital technology for some time.
But at Medica 2021 it felt like more exhibitors were realising the power of adding digital technology to their offer and there was a more widespread acceptance that this was the way forward in healthcare.
Covid-19 testing was obviously a huge focus for many exhibitors, with whole sections of their stands dedicated to it.
And, as you might expect, lateral flow was booming as a result, with at least twice as many exhibitors promoting tests as the last time I attended in 2019. As we’ve said before, the world is now truly awake to the potential of lateral flow.
It was also apparent that, like digital, home testing has come of age due to the pandemic. There were so many new home testing products being marketed, including tests for Covid-19, flu, and vitamin D.
Now people have become used to taking rapid tests at home, this market is finally on the verge of breaking through to the mainstream.
Despite the world catching up to what we’ve been promoting for the last few years, it was reassuring to see that Bond Digital Health’s data capture and management offer is still unique.
While more companies are now entering the digital space, most are only adding digital to their own tests. Our platform, Transform®, has been designed to be easily customised to work with any type of lateral flow test, for any purpose.
Thanks to the scalability of Transform®, companies can not only power a single test, but they can also easily add on new diagnostic tests, at no cost, to create entire portfolios that are digitally native.
Transform® enables innovation quickly and affordably because it is already built and is available on a subscription basis.
It’s in-market, working with actual tests, whereas many of the digital products at Medica were still in development.
What’s more, Transform® offers seamless public health reporting and is fully regulatorily compliant.
In terms of business, Medica was a fantastic opportunity to meet up in person with clients and partners for the first time in almost two years and catch up on the latest news.
I based myself on the Welsh Government stand but also toured the halls to meet people.
Attendance was slightly down on 2019, but as a result those who attended did so with an agenda and were there to do business.
As a result, I had lots of positive and productive meetings with representatives of companies from across the world.
And from those conversations one thing was clear – Bond is now a globally recognised business in the medtech space. Thanks to our partnerships, our products and our awards, people know who we are, what we do and how we can add value.
If you couldn’t make it to Medica, don’t worry, you can arrange to book a demo or speak to one of our experts at any time. Visit our website to see how.